10 diciembre 2014
A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The drug combination doubled the number of patients whose cancer had not progressed after one year from 14% to 28%, according to the study.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/UV5JZqiS9QA/141210131358.htm
